Jason C. Mixdorf

Jason C. Mixdorf

Auto-generated profile, based on publicly available information

Jason C. Mixdorf

Department of Chemistry , University of Iowa , Iowa City , Iowa 52242 , United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
QZQi Zhang
Qi Zhang
DSDavid P. Stockdale
David P. Stockdale
JMJason C. Mixdorf
Jason C. Mixdorf
JTJoseph J. Topczewski
Joseph J. Topczewski
HNHien M. Nguyen
Hien M. Nguyen


22 August 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ASAlexandre M. Sorlin
Alexandre M. Sorlin
JMJason C. Mixdorf
Jason C. Mixdorf
MRMadeline E. Rotella
Madeline E. Rotella
RMRobert T. Martin
Robert T. Martin
OGOsvaldo Gutierrez
Osvaldo Gutierrez
HNHien M. Nguyen
Hien M. Nguyen

1 September 2015 in Tetrahedron
Verified
Journal Article
Closed access
QZQi Zhang
Qi Zhang
JMJason C. Mixdorf
Jason C. Mixdorf
GRGilbert J. Reynders
Gilbert J. Reynders
HNHien M. Nguyen
Hien M. Nguyen

11 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ISIsidro Da Silva
Isidro Da Silva
TJTaylor R. Johnson
Taylor R. Johnson
JMJason C. Mixdorf
Jason C. Mixdorf
EAEduardo Aluicio-Sarduy
Eduardo Aluicio-Sarduy
TBTodd E. Barnhart
Todd E. Barnhart
PEPaul Ellison
Paul Ellison
Background: Radionuclides emitting Auger electrons (AEs) with low (0.02–50 keV) energy, short (0.0007–40 µm) range, and high (1–10 keV/µm) linear energy transfer may have an important role in the targeted radionuclide therapy of metastatic and disseminated disease. Erbium-165 is a pure AE-emitting radionuclide that is chemically matched to clinical therapeutic radionuclide 177Lu, making it a useful tool for fundamental studies on the biological effects of AEs. This work develops new biomedical cyclotron irradiation and radiochemical isolation methods to produce 165Er suitable for targeted radionuclide therapeutic studies and characterizes a new such agent targeting prostate-specific membrane antigen. Methods: Biomedical cyclotrons proton-irradiated spot-welded Ho(m) targets to produce 165Er, which was isolated via cation exchange chromatography (AG 50W-X8, 200–400 mesh, 20 mL) using alpha-hydroxyisobutyrate (70 mM, pH 4.7) followed by LN2 (20–50 µm, 1.3 mL) and bDGA (50–100 µm, 0.2 mL) extraction chromatography. The purified 165Er was radiolabeled with standard radiometal chelators and used to produce and characterize a new AE-emitting radiopharmaceutical, [165Er]PSMA-617. Results: Irradiation of 80–180 mg natHo targets with 40 µA of 11–12.5 MeV protons produced 165Er at 20–30 MBq·µA−1·h−1. The 4.9 ± 0.7 h radiochemical isolation yielded 165Er in 0.01 M HCl (400 µL) with decay-corrected (DC) yield of 64 ± 2% and a Ho/165Er separation factor of (2.8 ± 1.1) · 105. Radiolabeling experiments synthesized [165Er]PSMA-617 at DC molar activities of 37–130 GBq·µmol−1. Conclusions: A 2 h biomedical cyclotron irradiation and 5 h radiochemical separation produced GBq-scale 165Er suitable for producing radiopharmaceuticals at molar activities satisfactory for investigations of targeted radionuclide therapeutics. This will enable fundamental radiation biology experiments of pure AE-emitting therapeutic radiopharmaceuticals such as [165Er]PSMA-617, which will be used to understand the impact of AEs in PSMA-targeted radionuclide therapy of prostate cancer.

27 February 2024 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
WLWilson Lin
Wilson Lin
GCGerman Oscar Fonseca Cabrera
German Oscar Fonseca Cabrera
EAEduardo Aluicio-Sarduy
Eduardo Aluicio-Sarduy
TBTodd E. Barnhart
Todd E. Barnhart
JMJason C. Mixdorf
Jason C. Mixdorf
Jonathan W EngleJonathan W Engle
Jonathan W Engle